icon-folder.gif   Conference Reports for NATAP  
 
  EASL 2024
June 5-8, Milan, Italy
Back grey_arrow_rt.gif
 
 
 
No Amino Acid Substitution in HBV Pres1, HDAg, Or NTCP Associated With Suboptimal Response to Bulevirtide in Combination With Pegylated Interferon Alfa-2a Treatment in Participants With Chronic Hepatitis Delta: Results From MYR204, a Phase 2b Study
 
 
  European Association for the Study of the Liver; 05-08 June 2024; Milan, Italy
 
Yang Liu1, Silvia Chang1, Simin Xu1, Ross Martin1, Thomas Aeschbacher1, Savrina Manhas1, Roberto Mateo1, Lindsey May1, Dong Han1, Tahmineh Yazdi1, Caleb Marceau1, Christopher Richards1, Pui Yan Ho1, Chungfeng Li1, Clarissa Martinez1, Nadine Peinovich1, Andrew Lopez1, Dmitry Manuilov1, Renee-Claude Mercier1, Audrey H Lau1, Tarik Asselah2, Fabien Zoulim3, Evguenia Maiorova1, Hongmei Mo1 1Gilead Sciences, Inc., Foster City, CA, USA; 2H˘pital Beaujon APHP, UniversitÚ de Paris, INSERM, Clichy, France; 3Hepatology Department, Hospices Civils de Lyon, INSERM, UniversitÚ Claude Bernard Lyon 1, Lyon, France

0612241

0612242

0612243

0612244

0612245

0612246

0612247

0612248

0612249

06122410

06122411